In Oct 2007, the FDA introduced which the labeling for all PDE5 inhibitors, such as tadalafil, requires a much more notable warning on the possible threat of unexpected hearing reduction as the result of put up-internet marketing reviews of short term deafness connected to usage of PDE5 inhibitors.[